Effect of capecitabine on breast cancer patients with different estrogen receptor status
Bangladesh Journal of Pharmacology, 2020 This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status.
Gang Xu +5 more
doaj +1 more source
Cancer Treatment and Research Communications, 2023 Background: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer.
L. Bender +6 more
doaj +1 more source
Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. [PDF]
, 2012 Pancreatic neuroendocrine tumors (PNETs) are relatively rare tumors that arise in the endocrine cells of the pancreas. Historically, somatostatin analogues have been used in this disease primarily for symptom control and, to a limited extent, disease ...
Devata, Sumana, Kim, Edward J
core +2 more sources
Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?
Oncology Reviews, 2011 Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer. Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous infusion of 5-FU while avoiding complications and inconvenience of intravenous ...
Lakshmi Chintala +3 more
doaj +1 more source
Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. [PDF]
PLoS ONE, 2016 Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a meta ...
Ze-Chun Zhang +3 more
doaj +1 more source
Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]
, 2018 Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G. +5 more
core +1 more source
The Oncologist, 2007 Learning ObjectivesAfter completing this course, the reader will be able to: Identify the main toxicity profile associated with capecitabine therapy.Identify the main clinical indications for capecitabine therapy.Identify the populations at risk for severe toxicity from capecitabine therapy.CME Access and take the CME test online and receive 1 AMA PRA ...
openaire +4 more sources
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. [PDF]
, 2016 BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies.
Cortes, Javier +10 more
core +2 more sources
Therapeutic Advances in Medical Oncology, 2019 Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking.
Femke M. de Man +10 more
doaj +1 more source
The Impact of Capecitabine and Combined Training on BRCA1 Gene Expression in Breast Cancer Induction [PDF]
Journal of Basic Research in Medical Sciences, 2023 Introduction: This study explores the combined effects of concurrent training and capecitabine consumption on breast cancer prevention and therapy, focusing on the modulation of BRCA1 gene expression.
Masoud Shokuhi Niya +3 more
doaj